Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 6 April 2023, 17:32 HKT/SGT
Share:
    

Source: Eisai
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
As a Global Drug Discovery Center Aiming for Connecting Human and Human, and Data, and The World

TOKYO, Apr 6, 2023 - (JCN Newswire) - Eisai Co., Ltd. today announced the completion of a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan), which is a part of strategic investment to execute Eisai's medium-term business plan "EWAY Future & Beyond".

Eisai implements research and development activities under the DHBL (Deep Human Biology Learning) drug discovery and development system in our efforts to create new drugs based on innovative and efficient next-generation drug discovery concepts. For this purpose, we recognize diseases as Disease Continuum to redefine their concepts through comprehensive analysis on genomic, pathophysiological and clinical information associated with underlying causes of disease in order to enhance our understanding on human biology by acquiring data leading to next drug discovery with information, such as biomarkers and imaging data from patients on our drugs. Tsukuba Research Laboratories is positioned as a core facility in the DHBL drug discovery and development system. This renovation seeks to accelerate knowledge circulation by connecting each researcher with patients, other members within the Laboratories, other research sites across the world, and external researchers based on our key concept "Human Connected Laboratories: Laboratories Connecting Human and Human, and Data, and the World." Total investment on this major renovation was 8.5 billion yen.

Main Idea of This Major Renovation

[Designs to Enhancing Connection with Patients]
In the Eisai Group, all employees around the world use 1% of their total business hours to interact with patients (socialization) to understand their thoughts and feelings. Accordingly, we have been working on the initiatives (hhc activities) to lead value creation for patients. To enhance the opportunities for closer interaction with people outside the company, such as further socialization with patients, at Tsukuba Research Laboratories, a traffic line from the front gate through the main building lobby to the courtyard is placed as interactive zone to enable various communications.

[Realizing Connections between Researchers and Data Driven Drug Discovery]
In favor of generating natural communication between researchers across different therapeutic areas on a daily basis, workspaces for biology researchers and data scientists are allocated on the same floor, and likewise workspaces for chemistry and pharmacokinetics/analytical researchers are placed on nearby floors to foster new connections and knowledge exchange. Further creative solutions are implemented in laboratories, including collective arrangement of structural openings and devices. These designs facilitate data driven drug discovery through knowledge exchange.

[Knowledge Circulation Generated from Links between Buildings]
Corridors linking multiple buildings embodying the concept of Knowledge Circulation are placed. A traffic line named "Knowledge Corridor" enables people to move all around the laboratory, with which research efficiency and convenience are considerably improved.

[Meeting Rooms Value Connection with the World]
Each meeting room is equipped with an IT environment that allows smooth communication with overseas offices, as well as systems able to deal with hybrid meeting which dominantly accepted in recent days.

Eisai will accelerate the drug discovery activities under the DHBL drug discovery system in order to fulfill unmet medical needs, and in our efforts to further contribute to improve the benefits of patients and the people in the daily living domain.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

For more information, visit www.eisai.com/news/2023/news202328.html.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 15, 2025 09:03 HKT/SGT
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 7, 2025 08:14 HKT/SGT
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: